Before taking Zydelig(Idelalisib)

Zydelig therapy requires vigilant monitoring due to risks of severe and potentially fatal toxicities.

Critical Safety Precautions in Zydelig Administration

Zydelig is associated with significant risks, including hepatotoxicity, severe diarrhea or colitis, pneumonitis, and intestinal perforation. Liver function tests (ALT, AST, bilirubin) must be monitored frequently, especially during the first six months. 

Patients should be observed for new or worsening gastrointestinal, respiratory, or cutaneous symptoms, and blood counts should be checked regularly due to the risk of neutropenia. Zydelig should be discontinued permanently in cases of intestinal perforation, severe cutaneous reactions, or anaphylaxis. Concomitant use with strong CYP3A inducers or substrates should be avoided. Use in pregnancy and nursing is not recommended.